Geronimo Fernandez

Geronimo Fernandez

Auto-generated profile, based on publicly available information

Geronimo Fernandez

Aptus Biotech SL, Madrid, Spain

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
MPMaría del Carmen de Arriba Pérez
María del Carmen de Arriba Pérez
GFGerónimo Fernández
Gerónimo Fernández
ECEsteban Chacón-Solano
Esteban Chacón-Solano
MMManuel Mataix
Manuel Mataix
LMLucía Martínez-Santamaría
Lucía Martínez-Santamaría
MCMarta Carretero
Marta Carretero

1 January 2022 in Current HIV Research
Verified
Journal Article
Closed access
PDF file
WSWilliam Serumula
William Serumula
GFGeronimo Fernandez
Geronimo Fernandez
Victor GonzalezVictor Gonzalez
Victor Gonzalez
RPRaveen Parboosing
Raveen Parboosing
: Human Immunodeficiency Virus (HIV) infection continues to be a significant health burden in many countries around the world. Current HIV treatment through a combination of different antiretroviral drugs (cART) effectively suppresses viral replication, but drug resistance and crossresistance are significant challenges. This has prompted the search for novel targets and agents, such as nucleic acid aptamers. Nucleic acid aptamers are oligonucleotides that attach to the target sites with high affinity and specificity. This review provides a target-by-target account of research into anti-HIV aptamers and summarises the challenges and prospects of this therapeutic strategy, specifically in the unique context of HIV infection.